Mitogen-Activated Protein Kinases and Hypoxic/Ischemic Nephropathy

Cellular Physiology and Biochemistry

Volumn 39, Issue 3, 2016, Pages 1051-1067

  Luo, Fengbao ^a   Shi, Jian ^a   Shi, Qianqian ^a   Xu, Xianlin ^a   Xia, Ying ^b   He, Xiaozhou ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Hypoxia; Ischemia; Mitogen activated protein kinases; Nephropathy; Renal protection

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 3;

ACUTE KIDNEY FAILURE; BLOOD OXYGEN TENSION; CARCINOGENESIS; CHRONIC KIDNEY DISEASE; HUMAN; HYPOXIC ISCHEMIC NEPHROPATHY; KIDNEY DISEASE; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HYPOXIA; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOUSE; PATHOLOGY; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOGENESIS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KIDNEY; KIDNEY NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 7; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84983757587     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447812     Document Type: Review

References (132)

1. Segal SS: Regulation of blood flow in the microcirculation. Microcirculation 2005;12:33-45.
2. Singh P, Ricksten SE, Bragadottir G, Redfors B, Nordquist L: Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease. Clin Exp Pharmacol Physiol 2013;40:138-147.
3. Blantz RC, Deng A, Miracle CM, Thomson SC: Regulation of kidney function and metabolism: a question of supply and demand. Trans Am Clin Climatol Assoc 2007;118:23-43.
4. Fine LG, Bandyopadhay D, Norman JT: Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000;75:S22-26.
5. Bonomini M, Del Vecchio L, Sirolli V, Locatelli F: New Treatment Approaches for the Anemia of CKD. Am J Kidney Dis 2015;10.1053/j.ajkd.2015.06.030
6. Louis K, Hertig A: How tubular epithelial cells dictate the rate of renal fibrogenesis? World J Nephrol 2015;4:367-373.
7. Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C: Role of hypoxia in the pathogenesis of renal disease. Kidney Int 2005;10.1111/j.1523-1755.2005.09909.xS46-51.
8. Haase VH: Mechanisms of hypoxia responses in renal tissue. J Am Soc Nephrol 2013;24:537-541.
9. Feng Y, Liu Y, Wang L, Cai X, Wang D, Wu K, Chen H, Li J, Lei W: Sustained oxidative stress causes late acute renal failure via duplex regulation on p38 MAPK and Akt phosphorylation in severely burned rats. PLoS One 2013;8:e54593.
10. Potthoff SA, Fahling M, Clasen T, Mende S, Ishak B, Suvorava T, Stamer S, Thieme M, Sivritas SH, Kojda G, Patzak A, Rump LC, Stegbauer J: Angiotensin-(1-7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E-deficient mice. Hypertension 2014;63:265-272.
11. Aguilar-Alonso FA, Solano JD, Vargas-Olvera CY, Pacheco-Bernal I, Pariente-Perez TO, Ibarra-Rubio ME: MAPKs' status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate. Mol Cell Biochem 2015;404:161-170.
12. Kaufmann J, Martinka P, Moede O, Sendeski M, Steege A, Fahling M, Hultstrom M, Gaestel M, Moraes-Silva IC, Nikitina T, Liu ZZ, Zavaritskaya O, Patzak A: Noradrenaline enhances angiotensin II responses via p38 MAPK activation after hypoxia/re-oxygenation in renal interlobar arteries. Acta Physiol (Oxf) 2015;213:920-932.
13. Liu WH, Liu HB, Gao DK, Ge GQ, Zhang P, Sun SR, Wang HM, Liu SB: ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway. Cell Transplant 2013;22:1859-1868.
14. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-869.
15. Kyriakis JM, Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012;92:689-737.
16. Ma FY, Sachchithananthan M, Flanc RS, Nikolic-Paterson DJ: Mitogen activated protein kinases in renal fibrosis. Front Biosci (Schol Ed) 2009;1:171-187.
17. Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, Zhang H, Yu H, Swerdlow RH, Chen JX, Yan SS: Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim Biophys Acta 2014;1842:220-231.
18. Meng ZX, Wang L, Xiao Y, Lin JD: The Baf60c/Deptor pathway links skeletal muscle inflammation to glucose homeostasis in obesity. Diabetes 2014;63:1533-1545.
19. Kim EK, Choi EJ: Compromised MAPK signaling in human diseases: an update. Arch Toxicol 2015;89:867-882.
20. Yang M, Huang CZ: Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. World J Gastroenterol 2015;21:11673-11679.
21. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
22. Son Y, Kim S, Chung HT, Pae HO: Reactive oxygen species in the activation of MAP kinases. Methods Enzymol 2013;528:27-48.
23. Soares-Silva M, Diniz FF, Gomes GN, Bahia D: The Mitogen-Activated Protein Kinase (MAPK) Pathway: Role in Immune Evasion by Trypanosomatids. Front Microbiol 2016;7:183.
24. Cassidy H, Radford R, Slyne J, O'Connell S, Slattery C, Ryan MP, McMorrow T: The role of MAPK in drug-induced kidney injury. J Signal Transduct 2012;2012:463617.
25. Jha SK, Jha NK, Kar R, Ambasta RK, Kumar P: p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease. Int J Mol Cell Med 2015;4:67-86.
26. Ma MC, Qian H, Ghassemi F, Zhao P, Xia Y: Oxygen-sensitive {delta}-opioid receptor-regulated survival and death signals: novel insights into neuronal preconditioning and protection. J Biol Chem 2005;280:16208-16218.
27. Omori S, Hida M, Ishikura K, Kuramochi S, Awazu M: Expression of mitogen-activated protein kinase family in rat renal development. Kidney Int 2000;58:27-37.
28. Chen J, Wang W, Zhang Q, Li F, Lei T, Luo D, Zhou H, Yang B: Low molecular weight fucoidan against renal ischemia-reperfusion injury via inhibition of the MAPK signaling pathway. PLoS One 2013;8:e56224.
29. Chang NJ, Weng WH, Chang KH, Liu EK, Chuang CK, Luo CC, Lin CH, Wei FC, Pang ST: Genome-wide gene expression profiling of ischemia-reperfusion injury in rat kidney, intestine and skeletal muscle implicate a common involvement of MAPK signaling pathway. Mol Med Rep 2015;11:3786-3793.
30. Bokemeyer D, Guglielmi KE, McGinty A, Sorokin A, Lianos EA, Dunn MJ: Activation of extracellular signal-regulated kinase in proliferative glomerulonephritis in rats. J Clin Invest 1997;100:582-588.
31. Sirintrapun SJ, Geisinger KR, Cimic A, Snow A, Hagenkord J, Monzon F, Legendre BL Jr, Ghazalpour A, Bender RP, Gatalica Z: Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization. Medicine (Baltimore) 2014;93:e81.
32. Ahad A, Ahsan H, Mujeeb M, Siddiqui WA: Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells. Chem Biol Interact 2015;240:292-303.
33. Masaki T, Stambe C, Hill PA, Dowling J, Atkins RC, Nikolic-Paterson DJ: Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 2004;15:1835-1843.
34. Jiao Z, Chen J, Liu Y, Liu T, Chen K, Li G: Role of ERK1/2 and JNK phosphorylation in iodine contrast agent-induced apoptosis in diabetic rat kidneys. Ren Fail 2015;37:1349-1355.
35. Brady HR, Singer GG: Acute renal failure. Lancet 1995;346:1533-1540.
36. Charbonney E, Saudan P, Triverio PA, Quinn K, Mentha G, Martin PY: Prognosis of acute kidney injury requiring renal replacement therapy in solid organ transplanted patients. Transpl Int 2009;22:1058-1063.
37. Dennen P, Douglas IS, Anderson R: Acute kidney injury in the intensive care unit: an update and primer for the intensivist. Crit Care Med 2010;38:261-275.
38. Li Y, Zhong D, Lei L, Jia Y, Zhou H, Yang B: Propofol Prevents Renal Ischemia-Reperfusion Injury via Inhibiting the Oxidative Stress Pathways. Cell Physiol Biochem 2015;37:14-26.
39. Menke J, Sollinger D, Schamberger B, Heemann U, Lutz J: The effect of ischemia/reperfusion on the kidney graft. Curr Opin Organ Transplant 2014;19:395-400.
40. Legrand M, Mik EG, Johannes T, Payen D, Ince C: Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med 2008;14:502-516.
41. Yu W, Beaudry S, Negoro H, Boucher I, Tran M, Kong T, Denker BM: H2O2 activates G protein, alpha 12 to disrupt the junctional complex and enhance ischemia reperfusion injury. Proc Natl Acad Sci USA 2012;109:6680-6685.
42. Preising C, Schneider R, Bucher M, Gekle M, Sauvant C: Regulation of Expression of Renal Organic Anion Transporters OAT1 and OAT3 in a Model of Ischemia/Reperfusion Injury. Cell Physiol Biochem 2015;37:1-13.
43. Guan X, Qian Y, Shen Y, Zhang L, Du Y, Dai H, Qian J, Yan Y: Autophagy protects renal tubular cells against ischemia /reperfusion injury in a time-dependent manner. Cell Physiol Biochem 2015;36:285-298.
44. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000;256:34-41.
45. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183.
46. di Mari JF, Davis R, Safirstein RL: MAPK activation determines renal epithelial cell survival during oxidative injury. Am J Physiol 1999;277:F195-203.
47. Park KM, Chen A, Bonventre JV: Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem 2001;276:11870-11876.
48. Park KM, Kramers C, Vayssier-Taussat M, Chen A, Bonventre JV: Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem 2002;277:2040-2049.
49. Kwon DS, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK: Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells. Eur J Cell Biol 2006;85:1189-1199.
50. Kunduzova OR, Bianchi P, Pizzinat N, Escourrou G, Seguelas MH, Parini A, Cambon C: Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J 2002;16:1129-1131.
51. Yang CW, Ahn HJ, Jung JY, Kim WY, Li C, Choi BS, Kim HW, Kim YS, Moon IS, Kim J, Bang BK: Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. Transplantation 2003;75:20-24.
52. Li C, Wang T, Zhang C, Xuan J, Su C, Wang Y: Quercetin attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Gene 2016;577:275-280.
53. Hung CC, Ichimura T, Stevens JL, Bonventre JV: Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem 2003;278:29317-29326.
54. Chen HH, Lu PJ, Chen BR, Hsiao M, Ho WY, Tseng CJ: Heme oxygenase-1 ameliorates kidney ischemia-reperfusion injury in mice through extracellular signal-regulated kinase 1/2-enhanced tubular epithelium proliferation. Biochim Biophys Acta 2015;1852:2195-2201.
55. Park KM, Fogelgren B, Zuo X, Kim J, Chung DC, Lipschutz JH: Exocyst Sec10 protects epithelial barrier integrity and enhances recovery following oxidative stress, by activation of the MAPK pathway. Am J Physiol Renal Physiol 2010;298:F818-826.
56. Fogelgren B, Zuo X, Buonato JM, Vasilyev A, Baek JI, Choi SY, Chacon-Heszele MF, Palmyre A, Polgar N, Drummond I, Park KM, Lazzara MJ, Lipschutz JH: Exocyst Sec10 protects renal tubule cells from injury by EGFR/MAPK activation and effects on endocytosis. Am J Physiol Renal Physiol 2014;307:F1334-1341.
57. Jang HS, Han SJ, Kim JI, Lee S, Lipschutz JH, Park KM: Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury. Biochim Biophys Acta 2013;1832:1998-2008.
58. Weng X, Wang M, Chen H, Chen Z, Liu X: Ischemic postconditioning inhibits apoptosis of renal cells following reperfusion: a novel in vitro model. Int Urol Nephrol 2015;47:1067-1074.
59. Zou YR, Zhang J, Wang J, Peng L, Li GS, Wang L: Erythropoietin Receptor Activation Protects the Kidney From Ischemia/Reperfusion-Induced Apoptosis by Activating ERK/p53 Signal Pathway. Transplant Proc 2016;48:217-221.
60. Choi DE, Jeong JY, Lim BJ, Na KR, Shin YT, Lee KW: Pretreatment with the tumor nerosis factor-alpha blocker etanercept attenuated ischemia-reperfusion renal injury. Transplant Proc 2009;41:3590-3596.
61. Ka SO, Hwang HP, Jang JH, Hyuk Bang I, Bae UJ, Yu HC, Cho BH, Park BH: The protein kinase 2 inhibitor tetrabromobenzotriazole protects against renal ischemia reperfusion injury. Sci Rep 2015;5:14816.
62. Alderliesten M, de Graauw M, Oldenampsen J, Qin Y, Pont C, van Buren L, van de Water B: Extracellular signal-regulated kinase activation during renal ischemia/reperfusion mediates focal adhesion dissolution and renal injury. Am J Pathol 2007;171:452-462.
63. Zhuang S, Schnellmann RG: A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006;319:991-997.
64. Ma FY, Liu J, Nikolic-Paterson DJ: The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res 2009;42:29-37.
65. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA, Schreiner GF, Nikolic-Paterson DJ: Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol 2003;14:338-351.
66. Zhong Z, Hu Q, Fu Z, Wang R, Xiong Y, Zhang Y, Liu Z, Wang Y, Ye Q: Increased Expression of Aldehyde Dehydrogenase 2 Reduces Renal Cell Apoptosis During Ischemia/Reperfusion Injury After Hypothermic Machine Perfusion. Artif Organs 2015;10.1111/aor.12607
67. Ye S, Zhu Y, Ming Y, She X, Liu H, Ye Q: Glycyrrhizin protects mice against renal ischemia-reperfusion injury through inhibition of apoptosis and inflammation by downregulating p38 mitogen-activated protein kinase signaling. Exp Ther Med 2014;7:1247-1252.
68. Jung YJ, Lee AS, Nguyen-Thanh T, Kim D, Kang KP, Lee S, Park SK, Kim W: SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression. J Am Soc Nephrol 2015;26:1549-1560.
69. Lempiainen J, Finckenberg P, Mervaala EE, Storvik M, Kaivola J, Lindstedt K, Levijoki J, Mervaala EM: Dexmedetomidine preconditioning ameliorates kidney ischemia-reperfusion injury. Pharmacol Res Perspect 2014;2:e00045.
70. Walshe CM, Laffey JG, Kevin L, O'Toole D: Sepsis protects the myocardium and other organs from subsequent ischaemic/reperfusion injury via a MAPK-dependent mechanism. Intensive Care Med Exp 2015;3:35.
71. Wu SH, Chen XQ, Lu J, Wang MJ: BML-111 Attenuates Renal Ischemia/Reperfusion Injury Via Peroxisome Proliferator-Activated Receptor-alpha-Regulated Heme Oxygenase-1. Inflammation 2015;10.1007/s10753-015-0286-y
72. Kawakami T, Park SW, Kaku R, Yang J: Extracellular-regulated-kinase 5-mediated renal protection against ischemia-reperfusion injury. Biochem Biophys Res Commun 2012;418:603-608.
73. Nie H, Xue X, Li J, Liu X, Lv S, Guan G, Liu H, Liu G, Liu S, Chen Z: Nitro-oleic acid attenuates OGD/R-triggered apoptosis in renal tubular cells via inhibition of Bax mitochondrial translocation in a PPAR-gamma-dependent manner. Cell Physiol Biochem 2015;35:1201-1218.
74. Mutsaers HA, Stribos EG, Glorieux G, Vanholder R, Olinga P: Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. Front Med (Lausanne) 2015;2:60.
75. Li RX, Yiu WH, Tang SC: Role of bone morphogenetic protein-7 in renal fibrosis. Front Physiol 2015;6:114.
76. Fine LG, Norman JT: Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008;74:867-872.
77. Liu Y: Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011;7:684-696.
78. Rockey DC, Bell PD, Hill JA: Fibrosis-a common pathway to organ injury and failure. N Engl J Med 2015;372:1138-1149.
79. Nangaku M: Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
80. Orphanides C, Fine LG, Norman JT: Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. Kidney Int 1997;52:637-647.
81. Li X, Kimura H, Hirota K, Kasuno K, Torii K, Okada T, Kurooka H, Yokota Y, Yoshida H: Synergistic effect of hypoxia and TNF-alpha on production of PAI-1 in human proximal renal tubular cells. Kidney Int 2005;68:569-583.
82. Xie S, Chen H, Li F, Wang S, Guo J: Hypoxia-induced microRNA-155 promotes fibrosis in proximal tubule cells. Mol Med Rep 2015;11:4555-4560.
83. Sun S, Ning X, Zhai Y, Du R, Lu Y, He L, Li R, Wu W, Sun W, Wang H: Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway. Am J Nephrol 2014;39:436-448.
84. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M: Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 2004;65:871-880.
85. Du R, Xia L, Ning X, Liu L, Sun W, Huang C, Wang H, Sun S: Hypoxia-induced Bmi1 promotes renal tubular epithelial cell-mesenchymal transition and renal fibrosis via PI3K/Akt signal. Mol Biol Cell 2014;25:2650-2659.
86. Norman JT, Clark IM, Garcia PL: Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-2366.
87. Shen Y, Miao N, Xu J, Gan X, Xu D, Zhou L, Xue H, Zhang W, Lu L: Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. Int J Mol Sci 2016;17: pii: E146. doi: 10.3390/ijms17020146.
88. Qin J, Mei WJ, Xie YY, Huang L, Yuan QJ, Hu GY, Tao LJ, Peng ZZ: Fluorofenidone attenuates oxidative stress and renal fibrosis in obstructive nephropathy via blocking NOX2 (gp91phox) expression and inhibiting ERK/MAPK signaling pathway. Kidney Blood Press Res 2015;40:89-99.
89. Jung ES, Lee J, Heo NJ, Kim S, Kim DK, Joo KW, Han JS: Low-dose paclitaxel ameliorates renal fibrosis by suppressing transforming growth factor-beta1-induced plasminogen activator inhibitor-1 signaling. Nephrology (Carlton) 2016;10.1111/nep.12747
90. Kim S, Kim SJ, Yoon HE, Chung S, Choi BS, Park CW, Shin SJ: Fimasartan, a Novel Angiotensin-Receptor Blocker, Protects against Renal Inflammation and Fibrosis in Mice with Unilateral Ureteral Obstruction: the Possible Role of Nrf2. Int J Med Sci 2015;12:891-904.
91. Gao X, Wu G, Gu X, Fu L, Mei C: Kruppel-like factor 15 modulates renal interstitial fibrosis by ERK/MAPK and JNK/MAPK pathways regulation. Kidney Blood Press Res 2013;37:631-640.
92. Mei W, Peng Z, Lu M, Liu C, Deng Z, Xiao Y, Liu J, He Y, Yuan Q, Yuan X, Tang D, Yang H, Tao L: Peroxiredoxin 1 inhibits the oxidative stress induced apoptosis in renal tubulointerstitial fibrosis. Nephrology (Carlton) 2015;20:832-842.
93. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ: The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 2004;15:370-379.
94. Wang D, Warner GM, Yin P, Knudsen BE, Cheng J, Butters KA, Lien KR, Gray CE, Garovic VD, Lerman LO, Textor SC, Nath KA, Simari RD, Grande JP: Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model. Am J Physiol Renal Physiol 2013;304:F938-947.
95. Chen KH, Hsu HH, Yang HY, Tian YC, Ko YC, Yang CW, Hung CC: Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway. Int J Biochem Cell Biol 2016;10.1016/j.biocel.2016.03.001
96. Wei J, Li Z, Chen W, Ma C, Zhan F, Wu W, Peng Y: AEG-1 participates in TGF-beta1-induced EMT through p38 MAPK activation. Cell Biol Int 2013;37:1016-1021.
97. Ma FY, Tesch GH, Nikolic-Paterson DJ: ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. Am J Physiol Renal Physiol 2014;307:F1263-1273.
98. Xu W, Shao X, Tian L, Gu L, Zhang M, Wang Q, Wu B, Wang L, Yao J, Xu X, Mou S, Ni Z: Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp Ther 2014;350:552-562.
99. Wang W, Zhou PH, Xu CG, Zhou XJ, Hu W, Zhang J: Baicalein attenuates renal fibrosis by inhibiting inflammation via down-regulating NF-kappaB and MAPK signal pathways. J Mol Histol 2015;46:283-290.
100. Schodel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR: Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. Eur Urol 2015;10.1016/j.eururo.2015.08.007
101. Masoud GN, Li W: HIF-1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 2015;5:378-389.
102. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-421.
103. Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM: The role of HIF1alpha in renal cell carcinoma tumorigenesis. J Mol Med (Berl) 2014;92:825-836.
104. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-417.
105. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
106. Lee YH, Morrison BL, Bottaro DP: Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem 2014;289:20448-20461.
107. Lee HW, Joo KM, Lim JE, Cho HJ, Cho HJ, Park MC, Seol HJ, Seo SI, Lee JI, Kim S, Jeong BC, Nam DH: Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma. Mol Cancer Res 2013;11:1375-1386.
108. Chen Q, Lu HS, Gan MF, Chen LX, He K, Fan GM, Cao XQ: Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma. Asian Pac J Cancer Prev 2015;16:2495-2499.
109. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, Yoshida O: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-4187.
110. Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, Teh BT: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res 2008;68:81-88.
111. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999;274:32631-32637.
112. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS: The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000;60:4873-4880.
113. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J: MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-14019.
114. Hur E, Chang KY, Lee E, Lee SK, Park H: Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 2001;59:1216-1224.
115. Samaras V, Tsopanomichalou M, Stamatelli A, Arnaoutoglou C, Samaras E, Arnaoutoglou M, Poulias H, Barbatis C: Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations. Diagn Pathol 2009;4:7.
116. Suzuki K, Mizuno R, Suenaga K, Teruya T, Tanaka N, Kosaka T, Oya M: Bisebromoamide, an extract from Lyngbya species, induces apoptosis through ERK and mTOR inhibitions in renal cancer cells. Cancer Med 2013;2:32-39.
117. Sharma U, Pal D, Prasad R: A novel role of alkaline phosphatase in the ERK1/2 dephosphorylation in renal cell carcinoma cell lines: a new plausible therapeutic target. Biochimie 2014;107:406-409.
118. Han TD, Shang DH, Tian Y: Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma. Genet Mol Res 2016;15:doi: 10.4238/gmr.15017321.
119. Miyazaki A, Miyake H, Fujisawa M: Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clin Transl Oncol 2015;10.1007/s12094-015-1457-x
120. Zhang Z, Jiang T, Li Q, Wang J, Yang D, Li X, Wang Q, Song X: Nodal activates smad and extracellular signal-regulated kinases 1/2 pathways promoting renal cell carcinoma proliferation. Mol Med Rep 2015;12:587-594.
121. Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, Liu Z: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One 2013;8:e62823.
122. Hu W, Yuan Q, Liu XH, Zhu HC, Lv SQ, Wang XH: Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma. Eur J Pharmacol 2015;749:142-150.
123. Fang J, Wang H, Xi W, Cheng G, Wang S, Su S, Zhang S, Deng Y, Song Z, Xu A, Liu B, Cao J, Wang Z: Downregulation of tNASP inhibits proliferation through regulating cell cycle-related proteins and inactive ERK/MAPK signal pathway in renal cell carcinoma cells. Tumour Biol 2015;36:5209-5214.
124. Huang B, Fu SJ, Fan WZ, Wang ZH, Chen ZB, Guo SJ, Chen JX, Qiu SP: PKCepsilon inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett 2016;376:148-154.
125. Xu S, Guo P, Gao Y, Shi Q, He D, Gao Y, Zhang H: Acyldepsipeptides inhibit the growth of renal cancer cells through G1 phase cell cycle arrest. Biochem Biophys Res Commun 2013;438:468-472.
126. Cao Q, Chen M, Li Z, Huang W, Jin Y, Ye X, Tong M: High Novel Oncogene with Kinase-Domain (NOK) Gene Expression is Associated with the Progression of Renal Cell Carcinoma. Clin Lab 2016;62:179-186.
127. Hegazy MG, Emam MA: Ethanolic extract of Trigonella Foenum Graecum attenuates cisplatin-induced nephro-and hepatotoxicities in rats. Cell Mol Biol (Noisy-le-grand) 2015;61:81-87.
128. Kim HD, Yu SJ, Kim HS, Kim YJ, Choe JM, Park YG, Kim J, Sohn J: Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK. J Biol Chem 2013;288:28743-28754.
129. Jang JH, Min KJ, Kim S, Park JW, Kwon TK: RU486 Induces Pro-Apoptotic Endoplasmic Reticulum Stress Through the Induction of CHOP Expression by Enhancing C/EBPdelta Expression in Human Renal Carcinoma Caki Cells. J Cell Biochem 2016;117:361-369.
130. An J, Liu H, Magyar CE, Guo Y, Veena MS, Srivatsan ES, Huang J, Rettig MB: Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma. Cancer Res 2013;73:1374-1385.
131. Arias-Gonzalez L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparis-Ogando A, de la Cruz-Morcillo MA, Melgar-Rojas P, Garcia-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Gimenez-Bachs JM, Salinas-Sanchez AS, Pandiella A, del Peso L, Sanchez-Prieto R: ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia 2013;15:649-659.
132. Chaves Neto AH, Pelizzaro-Rocha KJ, Fernandes MN, Ferreira-Halder CV: Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O. Tumour Biol 2015;36:595-604.